Drug Trial Radar · NCT01339559
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
Last checked: Nov 20, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
767
Actual
Start
May 11, 2011
Primary completion
Apr 18, 2019
Study completion Apr 18, 2019
Sponsor
- Lead sponsor
- UCB BIOSCIENCES, Inc.UCB
- Sponsor type
- Industry
- First posted
- Apr 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).
Conditions
- Epilepsy
Interventions
BrivaracetamDrug
Tablet, Flexible dosing up to 200 mg/day, twice daily. The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
- Percentage of Participants Who Withdrew Due to Adverse Events (AEs)Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
- Percentage of Participants With at Least One Serious Adverse Event (SAE)Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)
Locations
184 sites in 28 countries. Site status is shown where the registry gives one.
001
Phoenix, Arizona
013
Phoenix, Arizona
006
Tucson, Arizona
775
Little Rock, Arkansas
025
San Francisco, California
060
Aurora, Colorado
071
Miami, Florida
027
Orlando, Florida
064
Port Charlotte, Florida
023
Atlanta, Georgia
048
Rome, Georgia
039
Boise, Idaho
029
Chicago, Illinois
005
Peoria, Illinois
017
Winfield, Illinois
020
Ames, Iowa
069
Iowa City, Iowa
780
Lexington, Kentucky
008
Bethesda, Maryland
068
Waldorf, Maryland
009
Golden Valley, Minnesota
032
Lebanon, New Hampshire
042
Hamilton, New Jersey
099
New York, New York
022
New York, New York
098
Poughkeepsie, New York
010
Asheville, North Carolina
003
Durham, North Carolina
034
Cleveland, Ohio
778
Columbus, Ohio
070
Columbus, Ohio
002
Toledo, Ohio
043
Oklahoma City, Oklahoma
091
Oklahoma City, Oklahoma
054
Tulsa, Oklahoma
015
Philadelphia, Pennsylvania
028
Charleston, South Carolina
021
Port Royal, South Carolina
776
Nashville, Tennessee
061
Austin, Texas
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.